Ribavirin analogs.
Ribavirin is ineffective against hepatitis C virus as mono-therapy but is critical in attaining both early virologic response and sustained virologic response when combined with pegylated interferon. Ribavirin has significant dose-limiting toxicities, the most important of which is hemolytic anemia. Taribavirin is a ribavirin pro-drug, which targets the liver and has less incidence of anemia, and it may be a promising alternative to ribavirin in the future.
Shields
William W
WW
Department of Gastroenterology and Hepatology, Naval Medical Center San Diego, San Diego, CA 92134, USA. william.shields@med.navy.mil
Pockros
Paul J
PJ
D000743:Anemia, Hemolytic / Q000139:chemically induced; D000998:Antiviral Agents / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*; D002219:Carbamates / Q000737:chemistry / Q000494:pharmacology; D016174:Hepacivirus / Q000187:drug effects; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D010671:Phenylurea Compounds / Q000737:chemistry / Q000494:pharmacology; D012254:Ribavirin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology
D000998:Antiviral Agents; D002219:Carbamates; C407002:N-3-(3-(3-methoxy-4-oxazol-5-ylphenyl)ureido)benzylcarbamic acid tetrahydrofuran-3-yl ester; D010671:Phenylurea Compounds; D012254:Ribavirin; D007168:IMP Dehydrogenase; C488211:IMPDH1 protein, human; D009173:Mycophenolic Acid; C026956:taribavirin